Wells Fargo

Wells Fargo’s RAPT Therapeutics RAPT Stock Holding History

Wells Fargo’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,138	Closed	-$1.22M	–	7666
2021 Q4	$1.22M	Buy	+4,138	New	+$1.11M	﹤0.01%	3968

Other funds holding RAPT

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Boone Capital Management Atlanta, Georgia $326M AUM 86.31% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Wells Fargo's RAPT Position: Q3 2025 in Review

Wells Fargo sold out of RAPT Therapeutics (RAPT) in Q3 2025, closing a stake of 1,229 shares — an estimated $9.83K sold.

Wells Fargo first reported a position in RAPT in Q4 2019 and held it in 22 quarters. The position peaked at $1.61M in Q3 2020. 65 funds tracked by Wall St. Rank hold RAPT as of Q3 2025.

Wells Fargo reported no remaining RAPT Therapeutics position as of Q3 2025 after selling out during the quarter.
Wells Fargo sold 1,229 RAPT Therapeutics shares in Q3 2025, an estimated $9.83K.
Wells Fargo first reported a position in RAPT Therapeutics in Q4 2019 and held it in 22 quarters.
Wells Fargo's RAPT Therapeutics position peaked at $1.61M in Q3 2020.
65 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2025.

Based on Wells Fargo's 13F filing for Q3 2025, filed 13 Nov 2025.